Imunon
Imunon

Imunon

Biotechnology
WebsiteInvestor RelationsSEC
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

$4.7M

Market Cap • 11/6/2026

1982

(44 years)

Founded

1995

(31 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

1,1

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

0,7

EPS

—

Market Cap

Market Cap

4,7M

EV

5,7M

EV/Revenue

0

EV/EBITDA

-0,4

EV/EBIT

-0,4

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-274,3%

Total Yield

-274,3%

Payout

0%

Retained Earnings

-428,4M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

10,8%

Capex/OCF

-0,5%

SBC/OCF

—

% PPE

8,3%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-100%

CAGR Op. Income 5Y

-5,2%

CAGR Net Income 5Y

-7,9%

CAGR EPS 5Y

-49,1%

CAGR OCF 5Y

0,1%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

1,8

Quick Ratio

1,4

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium